• DEVENEZ MEMBRE
    Pour un accès complet à theheart.org
    À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.

    L'abonnement est gratuit !
    Inscrivez-vous maintenant !
    Obtenez un accès limité de 30 jours aux articles de heartwire
    Professionnel de la santé   Oui Non
    Obtenez un accès limité !

ESC 2010 - Stockholm, Sweden

Heartwire

Arrhythmia/EP
European ECG screening criteria for young athletes need review
2 COMMENTS - Sep 13, 2010 13:45 EDT
Among studies in athletes presented at the recent ESC meeting, one suggested that individual ECG screening criteria are needed for different sports, and another concluded that marathon runners do not sustain any long-term damage to their hearts.
CTA and IVUS confirm that vulnerable plaques congregate in the proximal LAD
Imaging
CTA and IVUS confirm that vulnerable plaques congregate in the proximal LAD
1 COMMENT - Sep 9, 2010 15:30 EDT
A study of high-risk plaques with both virtual histology intravascular ultrasound and computed tomography angiography finds that that thin-cap fibroatheromas are focally distributed in the coronary arteries, especially located in the proximal left anterior descending coronary artery.
Interventional/Surgery
Clopidogrel-PPI interaction more relevant in noncarriers of CYP2C19 loss-of-function gene
4 COMMENTS - Sep 9, 2010 10:00 EDT
A small pharmacodynamic study has found that noncarriers of the CYP2C19 loss-of-function alleles were more susceptible than carriers to the effects of the PPI-clopidogrel interaction.
NSAID use associated with future stroke in healthy population
Brain/Kidney/Peripheral
NSAID use associated with future stroke in healthy population
16 COMMENTS - Sep 8, 2010 10:00 EDT
UPDATED // The results are in line with the increased risk of MI seen with NSAIDs and strengthen the need for more careful regulation of these drugs, the study author says.
First Europe-specific guidance on AF
Arrhythmia/EP
First Europe-specific guidance on AF
4 COMMENTS - Sep 7, 2010 17:15 EDT
The European Society of Cardiology announced new clinical guidelines for atrial fibrillation at its congress in Stockholm last week, the first time such recommendations have been prepared by European societies acting alone. Highlights include guidance on the use of dronedarone, better risk profiling for stroke in anticipation of new oral anticoagulants, the formal acceptance of ablation as a treatment option, and the recognition that lenient rate control is a satisfactory alternative to strict control.
Nurse program provides good RESPONSE for ACS secondary prevention
Acute Coronary Syndromes
Nurse program provides good RESPONSE for ACS secondary prevention
2 COMMENTS - Sep 3, 2010 13:15 EDT
Reasonably good results were obtained using nurses to counsel patients on secondary prevention after ACS, with a 17% relative reduction in calculated 10-year mortality over and above that achieved with usual care in the RESPONSE study. Although more work needs to be done to better refine such programs, they are feasible and can be easily implemented worldwide, said the researcher and other commentators.
ESC guidelines give top recommendation to CRT for mild heart failure
Heart failure
ESC guidelines give top recommendation to CRT for mild heart failure
4 COMMENTS - Sep 1, 2010 14:15 EDT
It's been in the wind on both sides of the Atlantic; now it's official in Europe: a class I A recommendation for cardiac resynchronization therapy for patients in sinus rhythm with NYHA class 2 systolic heart failure with a QRS duration >150 ms.
KYOTO and JIKEI HEART analyses show benefit of valsartan in Japanese hypertensive patients
Hypertension
KYOTO and JIKEI HEART analyses show benefit of valsartan in Japanese hypertensive patients
Sep 1, 2010 10:45 EDT
Adding valsartan to therapy in high-risk hypertensive patients reduced the risk of cardiovascular events more than conventional non-ARB treatment in both the primary- and secondary-prevention setting, according to an analysis from KYOTO HEART, while JIKEI HEART investigators suggest a benefit with valsartan in coronary artery disease patients.
Arrhythmia/EP
REALISE-AF registry: Much still to do in atrial fibrillation
1 COMMENT - Sep 1, 2010 10:00 EDT
Preliminary data from a new registry of more than 10 000 patients with AF, the largest ever, spanning 26 countries, shows that that much remains to be done in this field. AF is frequently not controlled, and even when it is, patients are often symptomatic. In addition, physicians need better guidance on how to treat AF, and better drug and devices are required, say experts.
Arrhythmia/EP
PACE: Dyssynchrony leads to lower ejection fraction in RVA-paced heart-failure patients
Sep 1, 2010 09:15 EDT
About half the patients in the PACE trial developed systolic dyssynchrony after a month of right ventricular apical pacing, leading to a reduced left ventricular ejection fraction.
Interventional/Surgery
Experts debate merits of DES for acute MI
1 COMMENT - Sep 1, 2010 07:30 EDT
Use of DES for AMI remains relatively low in Europe, despite short-term evidence pointing to reductions in target vessel revascularization. The problem is ascertaining likelihood of patient compliance to dual antiplatelet therapy in the middle of an emergency.
Dual-chamber pacing beats single-chamber pacing for sick sinus syndrome in DANPACE
Arrhythmia/EP
Dual-chamber pacing beats single-chamber pacing for sick sinus syndrome in DANPACE
Aug 31, 2010 10:30 EDT
Dual-chamber pacing results in fewer new surgeries and less AF than single-chamber pacing in patients with sick sinus syndrome in the DANPACE trial.
Arrhythmia/EP
ANTIPAF: ARB, on its own, doesn't suppress paroxysmal atrial fib
Aug 31, 2010 10:00 EDT
Patients with symptomatic paroxysmal atrial fibrillation who took the angiotensin-receptor blocker olmesartan didn't show any reduction in AF burden over the course of a year.
Thrombosis
Rivaroxaban almost superior to usual care in treatment of DVT
Aug 31, 2010 09:30 EDT
The new anticoagulant rivaroxaban has shown noninferiority to standard medical therapy in a large trial in the treatment of deep vein thrombosis, catching up with its rival dabigatran, for which similar data in this indication have already been reported.
AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding
Arrhythmia/EP
AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding
3 COMMENTS - Aug 31, 2010 06:55 EDT
Atrial-fibrillation patients in the trial treated with apixaban had a 54% lower risk of stroke or systemic embolic events, and, of note, the reduction came without an increase in bleeding events. The positive results now leave clinicians awaiting head-to-head comparisons of warfarin vs apixaban in the atrial-fibrillation setting.
Interventional/Surgery
FUTURA/OASIS-8: Standard-dose heparin recommended during PCI to avoid catheter thrombosis with fondaparinux
Aug 31, 2010 06:15 EDT
Results showed no major advantages of low-dose heparin over standard-dose heparin in such patients, and neither dose increased major bleeding compared with the historical control group of fondaparinux alone in the OASIS-5 trial.
Lipid/Metabolic
CTT meta-analysis: No cancer risk with statins, low LDL-cholesterol levels
Aug 30, 2010 16:30 EDT
Investigators report that statin therapy had no adverse effect on any cancer type, irrespective of how long patients took the cholesterol-lowering medications or their baseline LDL-cholesterol levels.
Interventional/Surgery
Colchicine halves incidence of postpericardiotomy syndrome
4 COMMENTS - Aug 30, 2010 15:00 EDT
The first large-scale double-blind, placebo-controlled trial to test the efficacy of colchicine to prevent the development of postpericardiotomy syndrome after heart surgery shows that the drug halves the risk of the condition developing.
Prevention
Four-year REACH analysis grasps a variety of clinical factors that flag atherothrombosis risk
1 COMMENT - Aug 30, 2010 14:15 EDT
The 45 277-patient REACH registry reveals a variety of risk factors that will help clinicians identify patients at high-risk for atherothrombosis.
ATOLL seen as supporting enoxaparin over standard heparin in primary PCI
Interventional/Surgery
ATOLL seen as supporting enoxaparin over standard heparin in primary PCI
3 COMMENTS - Aug 30, 2010 13:30 EDT
No man is an island, nor is any one study. In the case of ATOLL, the nonsignificant primary-end-point difference between enoxaparin and unfractionated heparin should be seen in the context of other studies suggesting the low-molecular-weight heparin is probably the better choice in the setting of PCI for STEMI, according to observers.
Interventional/Surgery
ART: Early results for bilateral IMA in CABG offer some promises, some concerns
1 COMMENT - Aug 30, 2010 12:15 EDT
One-year data from what the lead investigator characterized as one of the largest-ever randomized clinical trials of two CABG surgery techniques has found no differences in major clinical events between patients treated with either single internal mammary artery grafts or bilateral internal mammary arteries, but a higher rate of sternal wound reconstruction in the latter.
New class of antiplatelet agents in clinical trials
Acute Coronary Syndromes
New class of antiplatelet agents in clinical trials
Aug 30, 2010 11:30 EDT
A new, investigational antiplatelet agent, atopaxar—which acts via a different pathway from that of aspirin and drugs such as clopidogrel and ticagrelor—has shown promising results in a phase 2 trial. Another agent from the same class, vorapaxar, is already in phase 3 trials.
Interventional/Surgery
ISAR-REACT 3A: Lower heparin dose preferable in elective PCI
Aug 30, 2010 10:30 EDT
The 100-U/kg heparin dose was suggested to be better than the 140-U/kg dose and "noninferior" to bivalirudin in this trial with historical controls.
Acute Coronary Syndromes
INNOVATE PCI: Elinogrel, a new antiplatelet agent, passes initial hurdles
Aug 30, 2010 09:30 EDT
Investigators showed that treatment with oral and intravenous elinogrel had more rapid antiplatelet effects than clopidogrel in the acute and chronic phases of therapy. Although still in early days, the hope is that reversible platelet inhibition may mitigate some of the bleeding risks and improve clinical outcomes.
Interventional/Surgery
LESSON I: Everolimus bests sirolimus in nonrandomized DES face-off
3 COMMENTS - Aug 30, 2010 08:30 EDT
While the propensity-matched analysis narrowly missed its primary end point, secondary end points pointed to significant differences in MI rates that tracked with differences in stent thrombosis.
Exercise can treat cardiovascular disease as well as prevent it
Clinical cardiology
Exercise can treat cardiovascular disease as well as prevent it
13 COMMENTS - Aug 30, 2010 07:15 EDT
Experts presented research on exercise in patients who have already been diagnosed with cardiovascular disease, showing improvement on disease markers, not just subsequent events.
New PLATO data: No need for gene testing in PCI patients
Acute Coronary Syndromes
New PLATO data: No need for gene testing in PCI patients
1 COMMENT - Aug 29, 2010 13:00 EDT
New data from genetic substudies of PLATO and TRITON-TIMI 38 show that the efficacy of the new antiplatelet agents ticagrelor and prasugrel do not seem to be affected by loss-of-function genetic variants that contribute in some instances to worse outcomes in those on clopidogrel. Using these new agents means that routine testing for clopidogrel genetic variation is not necessary, say the authors and others; the new drugs should be used when possible in patients with a medium to high risk of thrombotic complications after stenting.
Heart failure
STAR-heart study: Stem cells associated with improved long-term hemodynamics and reduced mortality in chronic heart failure
Aug 29, 2010 11:30 EDT
UPDATED // The largest clinical trial so far of intracoronary autologous stem-cell transplantation in patients with chronic heart failure has shown that such treatment was associated with multiple hemodynamic and functional benefits as well as a reduction in mortality.
Acute Coronary Syndromes
EPO a no-go in post-MI patients: HEBE III
1 COMMENT - Aug 29, 2010 10:15 EDT
While the trial missed its primary end point, investigators report that erythropoietin did reduce major adverse cardiovascular events, a reduction driven primarily by a lower incidence of heart failure. They caution against making too much of this secondary finding, however, and say that larger phase 3 studies are still needed.
Interventional/Surgery
PCI gains ground for left main and multivessel disease in new ESC revascularization guidelines
Aug 29, 2010 09:30 EDT
In a first for the European Society of Cardiology, a new task force report on myocardial revascularization released today was jointly written with the European Association for Cardiothoracic Surgery and, with some seemingly more progressive and collaborative recommendations, reflects different practice patterns between the US and Europe.
Heart failure
PEARL-HF: New potassium-binding resin reduces hyperkalemia in heart failure
2 COMMENTS - Aug 29, 2010 08:15 EDT
Use of the new agent should enable many more patients to take lifesaving heart-failure treatments, but further dose adjustments may be necessary to reduce the risk of hypokalemia.
Acute Coronary Syndromes
CURE ACTIVE: No effect of loss-of-function clopidogrel gene on event rates in ACS or AF
Aug 29, 2010 08:00 EDT
UPDATED WITH COMMENTARY // However, a gain-of-function genotype was associated with a greater benefit of clopidogrel in the CURE trial, but not the ACTIVE A trial.
SHIFT: Adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalization
Heart failure
SHIFT: Adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalization
21 COMMENTS - Aug 29, 2010 05:00 EDT
UPDATED WITH COMMENTARY // The trial suggests that heart-rate reduction could become a clinically important goal and in fact a treatment target on its own in patients with chronic heart failure. Questions are raised, however, about how the patients who received ivabradine would have fared if more of them had been optimally treated with beta blockers.
Alpha Omega Trial: n-3 fatty acids fail to reduce cardiovascular events in post-MI patients
Lipid/Metabolic
Alpha Omega Trial: n-3 fatty acids fail to reduce cardiovascular events in post-MI patients
15 COMMENTS - Aug 29, 2010 02:00 EDT
UPDATED WITH COMMENTARY // The investigators say the negative findings are likely the result of the optimal medical therapy that patients in the trial were receiving following their index MI. All patients were treated with "state-of-the-art" therapy and this might explain the discrepancy with previous studies that suggested n-3 fatty acids, particularly EPA, might be cardioprotective following MI.
News
What's going to be hot at ESC 2010 Congress
3 COMMENTS - Aug 24, 2010 09:00 EDT
Attendance at this year's ESC Congress in Stockholm is showing early signs of beating last year's record of 32 000 attendees. This year's hot-line sessions, chosen from a record number of abstract submissions, include full details from the AVERROES trial of apixaban—top-line results of which were released early by the company—plus new randomized studies of ivabradine, erythropoietin in STEMI, and a long-term head-to-head comparison of two DES.

Discussion and opinions

Blogs
Clotblog with Dr Samuel Goldhaber
European clinical guidelines for atrial fibrillation
Nov 09, 2010 10:40 EST
The Bob Harrington Show
#28: AVERROES: Apixaban as a future alternative to warfarin with Dr Stuart Connolly
Oct 07, 2010 16:15 EDT
Cutting-edge dialogues with Drs Tim Gardner and Mat Williams
Recognizing the heart team: Surgeon and interventional cardiologist join forces for better outcomes
Sep 10, 2010 11:05 EDT
The Bob Harrington Show
#27: Elinogrel and INNOVATE PCI with Dr Sunil Rao
Sep 07, 2010 11:55 EDT
This week in cardiology from heartwire
#55: Top news from ESC 2010 Congress -- SHIFT on HR as target treatment...
Sep 03, 2010 15:25 EDT
Heart failure and transplantation with Dr Ileana Piña
Focus on exercise in older men and in women at ESC 2010
Sep 01, 2010 08:30 EDT
Heartfelt with Dr Melissa Walton-Shirley
ANTIPAF: Olmesartan doesn't suppress paroxysmal atrial fib; AVERROES: Apixaban gives significant reductions in stroke; DANPACE;...
Aug 31, 2010 18:15 EDT
Private practice with Dr Seth Bilazarian
Apixaban in AVERROES points the way to excellent alternatives to warfarin
Aug 31, 2010 17:45 EDT
Trials and PIs
DANPACE with Dr Jens C Nielsen
Aug 31, 2010 10:55 EDT
Trials and PIs
ANTIPAF with Dr Andreas Goette
Aug 31, 2010 10:41 EDT
Trials and PIs
AVERROES with Dr Stuart J Connolly
Aug 31, 2010 10:09 EDT
Trials and PIs
FUTURA OASIS 8 with Dr Sanjit Jolly
Aug 31, 2010 09:22 EDT
Trials and PIs
RESPONSE with Dr Ron J Peters
Aug 31, 2010 08:47 EDT
Trials and PIs
Double-blind, placebo-controlled phase 2 studies of E5555 in Japanese patients with ACS and CAD
Aug 31, 2010 08:34 EDT
Trials and PIs
ART with Dr David P Taggart
Aug 31, 2010 04:01 EDT
Trials and PIs
HEBE III with Dr A Voors
Aug 31, 2010 02:53 EDT
Heartfelt with Dr Melissa Walton-Shirley
Novel antiplatelets; optimal heparin dosing in ISAR-REACT 3A; elinogrel, a new antiplatelet, passes test in...
Aug 30, 2010 16:35 EDT
Heartfelt with Dr Melissa Walton-Shirley
Do something even if it's wrong? The case against unfractionated heparin
Aug 30, 2010 08:48 EDT
Trials and PIs
PCI: State of the art with Dr Sunil Rao
Aug 30, 2010 08:38 EDT
Trials and PIs
Bleeding Academic Research Consortium (BARC) with Dr Sunil Rao
Aug 30, 2010 08:30 EDT
Trials and PIs
INNOVATE PCI with Dr Sunil Rao
Aug 30, 2010 08:26 EDT
Trials and PIs
ISAR REACT 3A with Dr Gilles Montalescot
Aug 30, 2010 06:58 EDT
Trials and PIs
Meta-analysis of new thienopyridines with Dr Gilles Montalescot
Aug 30, 2010 06:19 EDT
Trials and PIs
ATOLL with Dr Gilles Montalescot
Aug 30, 2010 06:11 EDT
Heartfelt with Dr Melissa Walton-Shirley
PEARL-HF: RLY5016--A cure for hyperkalemia phobia and a help for needy CHF patients?
Aug 30, 2010 03:47 EDT
Heartfelt with Dr Melissa Walton-Shirley
STAR-heart study associates stem cells with improved hemodynamics and reduced mortality; PEARL-HF on reducing hyperkalemia...
Aug 29, 2010 16:25 EDT
Trials and PIs
ALPHA OMEGA with Dr Daan Kromhout
Aug 29, 2010 10:58 EDT
Heartfelt with Dr Melissa Walton-Shirley
The Alpha Omega fish-oil trial: Sabotaged by "greatness"?
Aug 29, 2010 10:40 EDT
Trials and PIs
PEARL HF with Dr Bertram Pitt
Aug 29, 2010 09:55 EDT
Trials and PIs
Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2...
Aug 29, 2010 09:31 EDT
Heartfelt with Dr Melissa Walton-Shirley
Thumbs-up for stem cells: Persistence finally pays off!
Aug 29, 2010 09:29 EDT
This week in cardiology from heartwire
#54: What's going to be hot at ESC 2010 Congress; Atrial fibrillation? Don't blame...
Aug 27, 2010 13:20 EDT
Private practice with Dr Seth Bilazarian
Four years on from the DES late-stent-thrombosis scare
Aug 25, 2010 09:20 EDT
Hot Line I - Heart failure and left ventricular dysfunction
Sunday, August 29, 11:00-12:30
Stockholm - Zone K

shim The STAR heart study: The acute and long-term effect of intracoronary stem-cell transplantation in 191 patients with chronic heart failure
Sunday, August 29 11:00-11:13
Bodo E Strauer Heinrich Heine University, Düsseldorf, Germany
  PEARL HF: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose study to evaluate the effects of RLY5016 in heart failure patients
Sunday, August 29 11:18-11:31
Bertram Pitt, University of Michigan, Ann Arbor, US
  SHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction
Sunday, August 29 11:36-11:49
Michel Komajda, Université Pierre et Marie Curie, Paris, France
  ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients
Sunday, August 29 11:54-12:07
Daan Kromhout, Wageningen University, the Netherlands
  HEBE III: A single dose of erythropoietin in ST-elevation myocardial infarction
Sunday, August 29 12:12-12:25
Adrian A Voors, University Medical Center Groningen, the Netherlands

Hot Line II - Coronary artery disease
Monday, August 30, 11:00-12:30
Stockholm Zone K

shim INNOVATE PCI: A phase II safety and efficacy study of PRT060128 (elinogrel), a novel intravenous and oral P2Y12 inhibitor, in non-urgent PCI (INNOVATE-PCI)
Monday, August 30, 11:00-11:10
Sunil Rao, Duke University Medical Center, Durham, NC
  ART: A randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting in coronary revascularization
Monday, August 30, 11:15-11:25
David P Taggart, John Radcliffe Hospital, Oxford, UK
  Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization
Monday, August 30, 11:30-11:40
Stephan Windecker, University Hospital, Bern, Switzerland
  ATOLL: An international, randomized trial comparing IV enoxaparin with IV unfractionated heparin in primary PCI for ST-elevation myocardial infarction
Monday, August 30, 11:45-11:55
Gilles Montalescot, Hôpital Pitié-Salpêtrière Paris, France
  ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions
Monday, August 30, 12:00-12:10
Stefanie Schulz, Deutsches Herzzentrum, Munich, Germany
  Double-blind, placebo-controlled phase II studies of E5555 in Japanese patients with acute coronary syndrome (ACS) and coronary artery disease (CAD)
Monday, August 30, 12:15-12:25
Shinya Goto, Tokai University, Isehara, Japan

Hot Line III - Cardiovascular disease and rhythm disturbances
Tuesday, August 31, 11:00-12:30
Stockholm Zone K

shim DANPACE: The Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome
Tuesday, August 31, 11:00-11:10
Jens C Nielsen, Aarhus University Hospital, Aarhus N, Denmark
  RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial
 Tuesday, August 31, 11:15-11:25
Ron J Peters, University of Amsterdam, the Netherlands
  AVERROES: Apixaban versus acetylsalicylic acid (ASA) to prevent strokes
Tuesday, August 31, 11:30-11:40
Stuart J Connolly, McMaster University, Hamilton, ON
  EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism
Tuesday, August 31, 11:45-11:55
Harry Buller, Academic Medical Center, Amsterdam, the Netherlands
  ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial
Tuesday, August 31, 12:00-12:10
Andreas Goette, Otto-von-Guericke-University Hospital, Magdeburg, Germany

  FUTURA OASIS 8: A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux
Tuesday, August 31, 12:15-12:25
Sanjit Jolly, McMaster University, Hamilton, ON
shim

Editorial programs

Heart-failure update from ESC 2010: SHIFT and new European guidelines for CRT
Editorial series
Heart-failure update from ESC 2010: SHIFT and new European guidelines for CRT
1 COMMENT - Oct 6, 2010 09:30 EDT
Drs Melissa Walton-Shirley, Clyde Yancy, and Cecilia Linde dissect the latest data on heart-failure treatment and talk about what the new European guidelines for CRT really mean.
Life and times of leading cardiologists with Rob Califf. Guest: Valentin Fuster
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Valentin Fuster
6 COMMENTS - Sep 29, 2010 09:00 EDT
Travel the world with Dr Valentin Fuster as he talks about growing up under Franco in Barcelona, the once-promising tennis career that inadvertently took him to Edinburgh, and his tenure at the Mayo Clinic and Mount Sinai.
The RESPONSE to secondary prevention
Editorial series
The RESPONSE to secondary prevention
1 COMMENT - Sep 22, 2010 09:00 EDT
Join Dr Melissa Walton-Shirley and guests Drs Kornelia Kotseva and Franz Messerli as they discuss issues raised by the RESPONSE trial.
CURRENT-OASIS 7, CURE, ACTIVE A, and INNOVATE PCI: Exploring the world of antiplatelet therapy
Editorial series
CURRENT-OASIS 7, CURE, ACTIVE A, and INNOVATE PCI: Exploring the world of antiplatelet therapy
1 COMMENT - Sep 15, 2010 15:30 EDT
Dr Keith Fox sits down with Dr Harvey White at the ESC 2010 Congress to discuss whether antiplatelet therapy is getting simpler or more complicated in light of new data presented.
ESC 2010 research highlights: A slideshow presentation
Editorial series
ESC 2010 research highlights: A slideshow presentation
3 COMMENTS - Sep 7, 2010 15:30 EDT
For a definitive overview of top clinical trials at ESC 2010 Congress, read our slideshow with the latest findings from AVERROES, SHIFT, ALPHA OMEGA, EINSTEIN DVT, FUTURA OASIS-8, LESSON 1, PLATO genetic substudies, CURE/ACTIVE A, INNOVATE PCI, ATOLL, COPPS, RESPONSE, and STAR-heart.
AVERROES, SHIFT, and the Alpha Omega Trial: The Stockholm Survey from ESC 2010
The Cardiology Show
AVERROES, SHIFT, and the Alpha Omega Trial: The Stockholm Survey from ESC 2010
Sep 1, 2010 11:25 EDT
Dr Valentin Fuster sits down with Drs Keith Fox, Kornelia Kotseva, Cecilia Linde, Franz Messerli, Harvey White, and Clyde Yancy to talk about the key trials presented at the ESC 2010 Congress.